Research, regulatory updates and industry perspectives to help you navigate a complex healthcare landscape.
Publications &
White Papers
2027 Medicare Physician Fee Schedule (PFS) Proposed Rule
The Impact on Drug Manufacturers and ASP
Once the Dust Settles on Q2 ASP Reporting
Documentation Updates Related to the New CMS ASP Reporting Requirements
The Current Landscape of Service-Fee FMV
A Regulatory, Compliance, and Financial Perspective of CMS’s Bona Fide Service Fee (BFSF) Framework
GP Compliance For Manufacturers in the Third Party Provider (TPP) Managed Services Environment
Helping to tell your GP Compliance Story
Maximum Fair Price (MFP) Effectuation for Part B Drugs
A Manufacturer-Focused Compliance Perspective and HELIO’s MFP Effectuation & Part B Drug Compliance Support
Government Programs Participation for Emerging Pharma and Biotech
A Case Study in Understanding Opportunities and Managing Risks: Will You be Ready on Day 1?
Applying Smart Technology to Class of Trade and 340B Validation
A Discussion of Recent HELIO Audits of COT Assignments and 340B Validations, and the Various Types of Issues Identified.
Government Programs Compliance "Health Check"
Evaluating your GP Audit Readiness Through Compliance Assessments to Identify Potential Gaps and Improve Documentation.
Navigating CAA 2026 PBM Reforms: Critical Concerns for Drug Manufacturers
An Overview of the 2026 Consolidated Appropriations Act and what the PBM Reforms mean for Pharmaceutical Manufacturers
Update on the CMS ASP Final Rule which goes into Effect Q1 2026
CMS Publishes a Holiday Gift with the Promised FAQ